Skip to main content

5th Advances in Circulating Tumor Cells (ACTC)

Novosanis is a silver sponsor and will be present at the 5th Advances in Circulating Tumor Cells (ACTC) conference in Kalamata, Greece. Stephanie Jordaens, our Biomedical Scientist, is excited to interact with researchers and industry experts from across the world and share the latest information on liquid biopsies, including urine in the field of oncology.

See you there!

Register here

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.